A cost effective strategy of bevacizumab in treatment of primary ovarian cancer — A subset analysis of ICON 7 trial

Objective: A subset analysis of ICON 7 showed that the addition of bevacizumab (B) and maintenance bevacizumab (mB) to paclitaxel (P) and carboplatin (C) improved the overall survival of stage IIIC (suboptimal) and stage IV ovarian cancer after primary surgery. Given the expense of B, we evaluated the cost effectiveness of B in this subset of patients.